down arrow

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100001M79
HKD
17.91
0.53 (3.05%)

Sep 23

HKG

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
The United Laboratories International Holdings Ltd.
Beijing Tong Ren Tang Chinese Medicine Co., Ltd.
Grand Pharmaceutical Group Ltd.
Simcere Pharmaceutical Group Ltd.
Luye Pharma Group Ltd.
SSY Group Ltd.
China Traditional Chinese Medicine Holdings Co. Ltd.
Shanghai Pharmaceuticals Holding Co., Ltd.
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
HUTCHMED (China) Ltd.
Keymed Biosciences, Inc.

Why is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ?

1
High Debt company with Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 1.53% of over the last 5 years
  • The company is Net-Debt Free
2
Flat results in Jun 26
  • RAW MATERIAL COST(Y) Grown by 17.29% (YoY)
  • DEBT-EQUITY RATIO (HY) Highest at 47.53 %
  • PRE-TAX PROFIT(Q) Lowest at HKD 1,112.47 MM
3
With ROE of 8.53%, it has a Very Expensive valuation with a 0.15 Price to Book Value
  • Over the past year, while the stock has generated a return of -31.80%, its profits have risen by 20.5% ; the PEG ratio of the company is 0.1
4
Underperformed the market in the last 1 year
  • Even though the market (Hang Seng Hong Kong) generated negative returns of -5.07% in the last 1 year, its fall in the stock was much higher with a return of -31.80%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai Fosun Pharmaceutical (Group) Co., Ltd. for you?

Medium Risk, High Return

Absolute
Risk Adjusted
Volatility
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
-100.0%
0.77
35.46%
Hang Seng Hong Kong
-5.07%
-0.27
18.67%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
5.82%
EBIT Growth (5y)
1.53%
EBIT to Interest (avg)
2.09
Debt to EBITDA (avg)
3.21
Net Debt to Equity (avg)
0.37
Sales to Capital Employed (avg)
0.54
Tax Ratio
24.10%
Dividend Payout Ratio
32.58%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
3.83%
ROE (avg)
9.03%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
2
Industry P/E
Price to Book Value
0.15
EV to EBIT
10.00
EV to EBITDA
4.11
EV to Capital Employed
0.38
EV to Sales
0.63
PEG Ratio
0.09
Dividend Yield
NA
ROCE (Latest)
3.81%
ROE (Latest)
8.53%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company
OPERATING CASH FLOW(Y)

Highest at HKD 10,512.31 MM

ROCE(HY)

Highest at 7.01%

CASH AND EQV(HY)

Highest at HKD 18,857 MM

INVENTORY TURNOVER RATIO(HY)

Highest at 3.57 times

EPS(Q)

Highest at HKD 0.74

-3What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 17.29% (YoY

DEBT-EQUITY RATIO (HY)

Highest at 47.53 %

PRE-TAX PROFIT(Q)

Lowest at HKD 1,112.47 MM

Here's what is working for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Operating Cash Flow
Highest at HKD 10,512.31 MM
in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (HKD MM)

EPS
Highest at HKD 0.74
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (HKD)

Cash and Eqv
Highest at HKD 18,857 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is improving

Cash and Cash Equivalents

Inventory Turnover Ratio
Highest at 3.57 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its inventory faster

Inventory Turnover Ratio

Here's what is not working for Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Pre-Tax Profit
Lowest at HKD 1,112.47 MM
in the last five periods
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (HKD MM)

Debt-Equity Ratio
Highest at 47.53 %
in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Raw Material Cost
Grown by 17.29% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales

Footer loading